Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Pfizer

Status: Completed

Conditions: Macular Degeneration

Treatments: Drug: Macugen

Study type: Observational

Funder types: Industry

Identifiers

NCT00460408

A5751019

Details and patient eligibility

About

The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.

Full description

No comparator Patients with age-related macular degeneration

Enrollment: 501 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neovascular AMD patients who are eligible for Macugen therapy based on the approved label

Exclusion criteria

• Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.

Trial design

501 participants in 1 patient group

Observational study, no comparator

Description:

Observational study of patients with AMD treated with Macugen, no comparator

Treatment:

Drug: Macugen